A Phase 1, Multi-Tumor, Bioavailability Study of Relatlimab in Combination With Nivolumab
Latest Information Update: 07 Apr 2023
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary) ; Hyaluronidase
- Indications Adenocarcinoma; Bladder cancer; Carcinoma; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 04 Apr 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2021 Planned primary completion date changed from 18 Aug 2022 to 17 Aug 2022.
- 13 Sep 2021 Status changed from recruiting to active, no longer recruiting.